A detailed history of Gradient Investments LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Gradient Investments LLC holds 112 shares of ALNY stock, worth $27,852. This represents 0.0% of its overall portfolio holdings.

Number of Shares
112
Previous 114 1.75%
Holding current value
$27,852
Previous $21,000 23.81%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$146.51 - $198.2 $293 - $396
-2 Reduced 1.75%
112 $16,000
Q3 2023

Oct 27, 2023

SELL
$170.77 - $211.65 $341 - $423
-2 Reduced 1.72%
114 $20,000
Q2 2023

Jul 11, 2023

BUY
$185.01 - $212.05 $1,110 - $1,272
6 Added 5.45%
116 $22,000
Q1 2023

Apr 17, 2023

SELL
$182.66 - $235.53 $182 - $235
-1 Reduced 0.9%
110 $22,000
Q4 2022

Jan 10, 2023

BUY
$185.53 - $241.31 $185 - $241
1 Added 0.91%
111 $0
Q2 2019

Jul 16, 2019

BUY
$65.86 - $92.79 $7,244 - $10,206
110 New
110 $8,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.6B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Gradient Investments LLC Portfolio

Follow Gradient Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gradient Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gradient Investments LLC with notifications on news.